# Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer

> **NCT04897009** · — · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 38 (actual)

## Conditions studied

- Invasive Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT04897009
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-09
- **Primary completion:** 2028-06-08
- **Final completion:** 2028-06-08
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04897009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04897009, "Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04897009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*